NanoMatrix

NanoMatrix, Inc. is a biotechnology company focused on developing biomimetic nanomatrix technologies for the treatment of cardiovascular and metabolic diseases. Spun out from the University of Alabama at Birmingham (UAB), the company's core platform utilizes proprietary peptide-amphiphile (PA) nanostructures that can be engineered to mimic the natural extracellular matrix and provide controlled release of therapeutic agents. NanoMatrix's lead programs target peripheral artery disease (PAD) and cardiovascular stents, aiming to improve clinical outcomes by reducing restenosis and promoting vascular healing through the localized delivery of nitric oxide. The company has received significant funding from the National Institutes of Health (NIH) through multiple SBIR grants to advance its regenerative medicine and drug delivery solutions.